97 results about "Antibody response" patented technology

The invention provides a micro-fluidic chip for combined detection of C-reactive protein and ferritin and application thereof.The micro-fluidic chip comprises a substrate and a cover plate pressed on the substrate, a micro-channel is defined by the substrate and the cover plate, the left end of the micro-channel is communicated with a buffer solution sample adding hole formed in the cover plate, the right end of the micro-channel is communicated with a waste liquid area, and the left end of the micro-channel is communicated with a buffer solution sample adding hole formed in the cover plate. The waste liquid area is provided with a movable water-absorbing paper sheet, the microchannel is sequentially provided with a marking area, a detection area and a sample adding area from left to right, the marking area is provided with a marked anti-human CRP antibody, a marked anti-human SF antibody, a marked second antibody and a marked antigen, the first detection site is provided with an anti-human CRP antibody, and the second detection site is provided with an anti-human SF antibody. The first reference point is provided with a first antibody which reacts with the labeled second antibody, the second detection site is provided with an anti-human SF antibody, and the second reference point is provided with an antibody which reacts with the labeled antigen. The detection process of C-reactive protein and ferritin can be simplified, and the detection time is shortened.

Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or a population of cells in a subject, methods of expressing a polypeptide of interest from a target genomic locus in a cell or a population of cells in a subject, methods of treating an enzyme deficiency in a subject in need thereof, and methods of preventing or reducing the onset of a sign or symptom of an enzyme deficiency in a subject in need thereof. The methods use CD40 inhibitors (e.g., CD40 antigen-binding molecules) to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting.

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.

Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or a population of cells in a subject, methods of expressing a polypeptide of interest from a target genomic locus in a cell or a population of cells in a subject, methods of treating an enzyme deficiency in a subject in need thereof, and methods of preventing or reducing the onset of a sign or symptom of an enzyme deficiency in a subject in need thereof. Some methods, such as when a subject has preexisting against an immunogen to be administered, use plasma cell depleting agents or combinations comprising plasma cell depleting agents to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting. Other methods, such as when a subject has no preexisting immunity against an immunogen to be administered, use B cell depleting agents (e.g., anti-CD20xCD3 antibody or functional fragment thereof) to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting.

The present invention relates to a multiplex immunoassay method for diagnosing autoimmune nodopathy and, more specifically, to a multiplex immunoassay method, comprising the steps of: (1) binding CNTN1, Caspr1, NF155, and NF186 proteins each to microspheres having different color codes; (2) mixing the microspheres having different color codes to which the proteins are each bound; (3) treating the mixed microspheres with a biological sample to induce an antigen-antibody reaction; (4) adding a detection antibody; and (5) reading fluorescence information of the microspheres to measure the presence or absence of anti-CNTN1 antibody, anti-Caspr1 antibody, anti-NF155 antibody, or anti-NF186 antibody in the biological sample and quantify amounts thereof, thereby enabling simultaneous testing of four antibodies for rapid diagnosis of autoimmune nodopathy.

The invention provides a pepsinogen II determination kit and a quantitative determination method, the kit comprises a reagent R1 and a reagent R2, the reagent R1 comprises a luminous donor molecule labeled pepsinogen II first antibody and a reaction buffer solution; and the R2 reagent comprises a light-emitting receptor molecule labeled pepsinogen II second antibody and a reaction buffer solution. A double-antibody sandwich structure marked by a luminescent donor and a luminescent receptor respectively is adopted, binding and luminescence can be completed in a liquid phase, solid phase coating and subsequent multi-step washing are not needed, real homogeneous detection and one-step incubation are achieved, the operation process is simplified, the detection time is shortened, and a full-automatic platform is adapted; and an improved buffer system can inhibit non-specific adsorption and reduce heterotropism interference such as RF / HAMA, so that the detection accuracy and repeatability are improved.

Featured are the use of pharmaceutical compositions containing a CD40 antagonist or a CD154 antagonist for the treatment, reduction, and / or inhibition of an immune response, such as an anti-drug antibody response, following, e.g., protein replacement therapy or gene therapy.

The invention provides a method for determining an extinction coefficient of a toxin connexon in an antibody-coupled drug and a method for detecting a drug-antibody coupling ratio in the antibody-coupled drug. The method for measuring the extinction coefficient comprises the following steps: a) dissolving a toxin connexon in a solvent to obtain a toxin connexon solution; b) respectively mixing the concentration toxin connexon solution and the solvent with the excessive antibody solution to obtain a toxin connexon reaction solution and an antibody negative control solution; c) completely reacting the toxin connexon with the antibody; d) carrying out baseline calibration by using the antibody negative control solution as a reference solution and scanning a toxin linker reaction solution absorption spectrum; and e) drawing a linear curve of the absorbance of the toxin connexon and the concentration of the toxin connexon, fitting to obtain a linear equation, and the slope of the linear equation being the extinction coefficient of the coupled toxin connexon. The method can solve the problem that the extinction coefficient of the toxin connexon in the antibody-coupled drug is difficult to accurately determine in the prior art, and is suitable for the field of antibody-coupled drug analysis.

An ionizable cationic lipid compound having a structure represented by formula (I), which can be used to prepare lipid nanoparticles (LNP) for the delivery of a therapeutic and / or prophylactic agent. The LNP prepared using the ionizable cationic lipid compound has good stability and transfection efficiency, and can efficiently and stably deliver bioactive substances (including nucleic acids, such as mRNA) to target cells or organs, thereby eliciting a high-specificity antibody response in vivo.

Disclosed are a method for detecting sugi allergen-specific IgE antibodies in a body fluid sample, which can improve the detection value of sugi allergen-specific IgE antibodies, and a kit for use therein. The method comprises the following steps: a removal step for removing non-IgE antibodies such as IgG antibodies from the body fluid sample; a reaction step for contacting the antibody-removed body fluid sample obtained in the removal step with a reaction well on a substrate having a reaction well, thereby forming a complex between the allergen and the allergen-specific IgE antibody; the reaction well comprising a region immobilizing the sugi allergen and regions immobilizing one or more allergens other than the sugi allergen; and a detection step for detecting the complex between the sugi allergen and the sugi allergen-specific IgE antibody obtained in the reaction step.

The present disclosure discloses a detection kit and a preparation method thereof and a detection method for novel coronavirus, and relates to the technical field of biomedicine, including an antigen test strip. The antigen test strip includes a substrate, bibulous paper, immune nitrocellulose membrane, and immune microsphere pad. The immune microsphere pad, the immune nitrocellulose membrane and the bibulous paper are pasted on the substrate. The immune microsphere pad is coated with latex microsphere-labeled novel coronavirus SARS-CoV-2 monoclonal antibody 1. The immune nitrocellulose membrane is provided with a test line coated with novel coronavirus SARS-CoV-2 monoclonal antibody 2 and a quality control line coated with goat anti-mouse IgG polyclonal antibody. The present disclosure uses latex particles as labeled tracer, and uses antigen-antibody reaction and lateral chromatography to detect and analyze targets, having advantages of convenience and swift.

AAV vectors are ideally suited for long-term delivery of a combination of broadly neutralizing antibodies to achieve sterilizing immunity to HIV. Unfortunately, host immune responses to the delivered antibody have severely limited the efficacy. The TLR9 pathway has been identified in initiating adaptive immune responses against AAV and delivered bNAbs. To enhance this strategy, we validated Hydroxychloroquine, a known drug inhibitor of the TLR9 pathway, as a pretreatment to AAV delivery to avoid anti-drug antibody responses. TLR9 signaling inhibition was validated using a HEK-Blue hTLR9 reporter cell line and CpG stimulation. Hydroxychloroquine was also validated in a 3-macaque trial where AAV9-3BNC117 and AAV9-10-1074 were administered along with 3 doses of hydroxychloroquine once a week starting 1 week before AAV inoculation. Unlike historical controls, where 3BNC117 and 10-1074 expression is lost within the first 4-5 weeks, 2 macaques maintained 10-1074 expression and 1 macaque maintained 3BNC117 for the duration of the trial. Anti-3BNC117 antibodies were only observed in 2 of the 3 macaques and were significantly delayed. Anti-10-1074 antibody responses were a log lower than typically observed in historic controls. The use of hydroxychloroquine as a pretreatment for AAV inoculation is a promising strategy. The significant decrease in anti-10-1074 antibody levels and the successful delivery of 10-1074 in 2 macaques and 3BNC117 in 1 macaque was very encouraging. Extending the dosage of hydroxychloroquine beyond 3 doses may be sufficient to observe long-term bNAb expression in all animals and further decrease ADA responses. Together, these data suggest that the short-term treatment of hydroxychloroquine at the time of AAV inoculation has a meaningful impact on tolerance induction to our AAV-delivered bNAbs.

This invention relates to the field of reaction chamber technology, specifically an antigen-antibody reaction chamber, comprising a chamber body with three mounting openings on the outside for mounting windows one, two, and three, respectively. The cross-section of the chamber body is an outer shell, and the top of the outer shell has a top mechanism with rotating pins at both ends inserted into the two sides of the top of the outer shell. One side of the lower outer wall of the top of the outer shell is connected to an antigen chamber, and the other side is connected to an antibody chamber. The lower parts of the antigen chamber and antibody chamber are connected to the second air bladder of the reaction device via gas inlet tubes. The soft baffle in the inlet initially touches the inlet of the inlet tube, and then the inlet begins to break through the soft baffle, causing the reagent inside the antigen chamber to flow out along the long tube and then into the reaction device. The antigen reagent and the antibody reagent flowing into the reaction device at the same time specifically bind, thereby accelerating the specific binding rate of antigen and antibody inside the reaction device.

The present invention provides a method for determining the extinction coefficient of a toxin linker in an antibody-drug conjugate and a method for detecting the drug-antibody conjugation ratio in an antibody-drug conjugate. The method for determining the extinction coefficient comprises: a) dissolving the toxin linker in a solvent to obtain a toxin linker solution; b) mixing the concentrated toxin linker solution and the solvent with an excess antibody solution to obtain a toxin linker reaction solution and an antibody negative control solution; c) allowing the toxin linker to react completely with the antibody; d) using the antibody negative control solution as a reference solution for baseline calibration and scanning the absorption spectrum of the toxin linker reaction solution; and e) plotting a linear curve of the toxin linker absorbance and toxin linker concentration, fitting the curve to obtain a linear equation, and the slope of the linear equation is the extinction coefficient of the toxin linker after conjugation. This method can solve the problem of the difficulty in accurately determining the extinction coefficient of the toxin linker in an antibody-drug conjugate in the prior art and is suitable for the field of antibody-drug conjugate analysis.

The application discloses a red blood cell adhesion enhancer, wherein 1000 mL of the red blood cell adhesion enhancer comprises the following components: 0.5-2.0 g of sodium chloride, 2.0-5.0 g of disodium ethylenediaminetetraacetate, 1.0-3.0 g of sodium citrate, and the rest is ultrapure water. The red blood cell adhesion enhancer and the cell suspension of washed human packed red blood cells can be used for preparing a solid-phase agglutination reaction microplate. Compared with a traditional "normal saline-red blood cell" suspension, the cell suspension constructed by the red blood cell adhesion enhancer and the human packed red blood cells can significantly increase the number of red blood cells adhered to the surface of a solid-phase microplate carrier, ensure the sufficient and stable number of adhered red blood cell antigens in a long-term storage process of the solid-phase microplate, ensure the number of red blood cell antigens reacted with a to-be-tested antibody, improve the sensitivity of the solid-phase agglutination reaction, avoid false negatives caused by missed detection of the same antibody, and reduce the risk of blood transfusion.

Viruses, bacteria, and parasites frequently cause infections in the gastrointestinal (GI) tract, but traditional vaccination strategies typically elicit little or no mucosal antibody responses. Disclosed herein is a vaccine comprising a nanoemulsion and an immunogen non-covalently conjugated to the surface of the nanoemulsion by an amphiphilic linker, wherein the vaccine is suitable for inducing a mucosal antibody response in the gastrointestinal tract. Also disclosed are methods of using the vaccine to immunize a subject by intraperitoneal administration of an effective amount of the vaccine, alone or with an adjuvant.

The application discloses a kind of natural product antiviral drug screening method based on hexagon protein and application, belong to active ingredient screening and antiviral drug development field.The method includes: preparation nitrogen-doped mesoporous carbon and silver nanosheet composite solution, drop coating on the surface of pretreated glassy carbon electrode, after drying by activation, hexagon protein incubation, blocking and enzyme label antibody reaction, construct electrochemical sensing electrode;With the electrode, the sample to be screened natural product is incubated, and the current response signal is detected;According to signal change combination inhibition rate formula evaluation antiviral activity.The application takes hexagon protein as recognition target, based on the principle of competitive immunoassay, realizes the specific, high sensitivity detection of antiviral active ingredient in natural product, with the advantages of fast operation, low cost, small sample consumption, high throughput, etc., provides effective technical support for the mining of antiviral active ingredient in natural product such as traditional Chinese medicine.

The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which comprise a stretch of consecutive negative amino acids selected from aspartic acid and / or glutamic acid to which specific Interleukin- 1β mutein antigens, IL-1β-D145X antigens, are linked, as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccines for generating immune responses, in particular antibody responses, against IL-1β.

The invention belongs to the technical field of vaccines, and particularly relates to a manganese-based platelet carrier vaccine based on a biomimetic mineralization technology and application of the manganese-based platelet carrier vaccine in immunotherapy. A manganese-based shell is deposited on the surface of a platelet, immunocompetence molecules such as CD40L and PF4 are expressed on the surface of the platelet, dendritic cells (DC) can be activated by directly contacting or secreting cell factors, and antigen presentation is promoted; in addition, deposited manganese ions can activate a cGAS-STING pathway, and meanwhile, CD40 / CD80 / CD86 / MHC-II costimulatory molecular expression on the surface of the DC is up-regulated. The vaccine adjuvant provided by the invention can be used for loading an antigen to form a three-in-one vaccine complex of the antigen (loaded on a platelet membrane), the platelet and a manganese shell, so that not only is the natural targeting capability of the platelet retained, but also DC cross presentation is enhanced through continuous release of manganese ions, finally CD8 + T cells are synergistically activated to react with an antibody, and the immune response of the antigen is enhanced. The antiviral immune response of the body is enhanced.

The article related to this design is a specimen sensor device used in an electrochemical measuring instrument, and in particular, it is a disposable specimen sensor device used in immunological tests utilizing antigen-antibody reactions. This specimen sensor device is for detecting antigens and antibodies in body fluids, protein concentrations in food raw materials / processed products, and the like. This specimen sensor device includes a dropping port for dropping a solution containing a test substance, a viewing window through which the flow of the solution can be visually recognized, a ventilation port for confirming a wetness determination line and for ventilation, and an electrode connector substrate for insertion into an electrochemical measuring instrument.

The present invention proposes a microfluidic chip for the combined detection of C-reactive protein and ferritin and its application. The chip comprises a substrate and a cover sheet pressed onto the substrate. The substrate and cover sheet enclose a microchannel. The left end of the microchannel is connected to a buffer injection hole provided on the cover sheet, and the right end is connected to a waste liquid area. The waste liquid area is provided with a removable absorbent paper sheet. The microchannel is provided with a labeling area, a detection area, and a sample injection area from left to right. The labeling area is provided with a labeled anti-human CRP antibody, a labeled anti-human SF antibody, a labeled second antibody, and a labeled antigen. The first detection site is provided with an anti-human CRP antibody, the first reference point is provided with a first antibody that reacts with the labeled second antibody, the second detection site is provided with an anti-human SF antibody, and the second reference point is provided with an antibody that reacts with the labeled antigen. This can simplify the detection process of C-reactive protein and ferritin and shorten the detection time.

This invention provides a method for preparing a non-natural humanized chimeric anti-human CD45RA antigen receptor, which specifically binds to the human CD45RA antigen by expressing CAR protein on T cells. Based on a humanized 3A4 antibody, this invention constructs a lentiviral expression vector pLenti / Hu3A4-4-1BB-3ζ. Compared with murine CAR, the humanized CAR significantly reduces immunogenicity, noticeably decreases the production of anti-scFv antibodies, and avoids the HAMA reaction. Research results show that Hu3A4CAR-T cells can specifically bind to the CD45RA-highly expressing myeloid leukemia cell line KG1a. Hu3A4CAR-T cells can target and kill 3A4-positive cell lines and leukemia cells, alleviate the human anti-mouse antibody response, and significantly reduce the production of anti-scFv antibodies, thereby ensuring the CAR's killing activity.

The present application relates to a specimen extraction solution and a specimen extraction method, and an inspection reagent using the same, the specimen extraction solution containing a component capable of inhibiting false negative reactions that cannot be completely inhibited by conventional methods when detecting antigens such as viruses, bacteria, and proteins to be detected from specimens from body fluids such as a nasal swab specimen, a nasal aspirate specimen, a nasal lavage specimen, a nasal discharge specimen, a throat swab specimen, a saliva specimen, a fecal specimen, a serum specimen, a plasma specimen, a urine specimen, and the like using an inspection reagent that utilizes antigen-antibody reactions or reactions of substances having interactions with each other. The specimen extraction solution of the inspection reagent, or a component that comes into contact with a specimen in a process before a detection reaction of a detection object or a process performed simultaneously with the detection reaction, and the like contain a water-soluble compound having a phenyl group, a benzyl group, a tolyl group, or a xylyl group in the structure, and at least a functional group including a carboxyl group or a carboxyl group methylated or ethylated atom group or a hydroxyl group bonded to the above group.

An anti-rabies virus immunogen composition capable of simultaneously inducing a humoral immune response and a cellular immune response and a use thereof. The anti-rabies virus immunogen composition involves a dual-immunogen combination, comprising a rabies virus glycoprotein G as an immunogen for activating neutralizing antibodies and a polymerase large protein L as a T-cell immunogen. The rabies virus glycoprotein is derived from the full length of a glycoprotein or extracellular region amino acids thereof or an antigenic fragment thereof, and the T-cell immunogen is derived from a recombinant sequence of a conserved region of a polymerase large protein. Optionally, the two immunogens are loaded onto the same type of carrier or different types of carriers. The vaccine is safe and can simultaneously activate anti-rabies virus T cells and an antibody response, thereby realizing combined protection for preventing and treating rabies virus infection.

This invention provides a recombinant Staphylococcus aureus enterotoxin B nanoparticle protein vaccine, mSEB-mi3, its preparation method, and its applications. This invention utilizes a SpyTag / SpyCather protein linker system to connect the recombinant protein to the nanoparticle protein, allowing mSEB to be displayed on the surface of self-contained nanoparticles, thus obtaining the recombinant Staphylococcus aureus enterotoxin B nanoparticle protein mSEB-mi3. Both mSEB-SpyTag and SpyCather-mi3 proteins in this invention are induced to be expressed in soluble form in Escherichia coli. The mSEB-SpyTag and SpyCather-mi3 of this invention can be covalently bound via isopeptide bonds to form the mSEB-mi3 nanoparticle protein vaccine. The binding conditions are simple, and when combined with the adjuvant MF59, it can induce rapid antibody production in mice, generating a high-level immune response and exerting a protective effect. Furthermore, its antibody response rate and protective efficiency are superior to those of the monomeric protein mSEB.

The application discloses a kind of pet immunopotentiating nutrition cream and its preparation method and application, and is related to pet health care technical field, component includes astragalus polysaccharide 5 parts, salvia extract 0.5 parts, palm ginseng powder 0.05 parts, chicken oil 3 parts, chicken 2 parts, flaxseed oil 15 parts, lysophospholipid 12 parts, sucrose fatty acid ester 7 parts, sodium chloride 3 parts, yeast iron 0.6 parts, sodium carboxymethyl cellulose 8 parts, potassium sorbate 0.18-0.20 parts, ethylenediaminetetraacetic acid disodium 0.023-0.025 parts, compound B group vitamin 0.0011-0.0013 parts, fructose syrup 0.5 parts, butylated hydroxyanisole (BHA) 0.02 parts, malt dextrin 50 parts, the nutrition cream of the application has the characteristics of immunopotentiating effect, high absorption and utilization rate, good palatability, stability and high safety, significantly improve pet immunoglobulin level (IgG, IgM, IgA is increased by 278%, 417%, 555% respectively), enhance vaccine antibody response (cat plague antibody is increased by 71%), improve cellular immune function (T cell proliferation ability is increased by 66%, CD4+ / CD8+ Ratio is significantly increased).

The present disclosure provides non-naturally occurring, broadly reactive, pan-epitope antigens derived from H3 influenza viruses, which are immunogenic and capable of eliciting a broadly reactive immune response against H3 viruses, such as a broadly reactive neutralizing antibody response, in a subject upon introduction. The present disclosure also provides non-naturally occurring, broadly reactive immunogens, vaccines, virus-like particles (VLPs), and compositions comprising the immunogens and vaccines. The present disclosure provides methods of generating an immune response in a subject by administering an immunogen, vaccine, VLP, or a composition thereof. In particular, the immunogen comprises the hemagglutinin (HA) protein of an H3 influenza virus strain.

Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or a population of cells in a subject, methods of expressing a polypeptide of interest from a target genomic locus in a cell or a population of cells in a subject, methods of treating an enzyme deficiency in a subject in need thereof, and methods of preventing or reducing the onset of a sign or symptom of an enzyme deficiency in a subject in need thereof. Some methods, such as when a subject has preexisting against an immunogen to be administered, use plasma cell depleting agents or combinations comprising plasma cell depleting agents to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting. Other methods, such as when a subject has no preexisting immunity against an immunogen to be administered, use B cell depleting agents (e.g., anti-CD20xCD3 antibody or functional fragment thereof) to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting.

The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which comprise a stretch of consecutive negative amino acids selected from aspartic acid and / or glutamic acid to which canine Interleukin-1β mutein antigens, cIL-1β-D145X antigens, are linked, as well as pharmaceutical compositions thereof, which compositions preferably serve as vaccines for generating immune responses, in particular antibody responses, against cIL-1β.

The present embodiments provide for an S. aureus (SA). Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces a B-cell and T-cell immune response, where at least one S. aureus (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. The present SA-MAPS immunogenic composition herein generates an immune response in a subject, preferably an antibody response and a B-cell and / or T-cell response, and can comprise at least one B-cell SA antigen and at least one T-cell SA antigen, and can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one, or multiple SA antigens at the same time.